Cytokinetics to Participate in March Investor Conferences
Rhea-AI Summary
Cytokinetics (NASDAQ: CYTK) said members of its management team will participate in four investor events in Miami Beach in March 2026: Leerink Global Healthcare (fireside, Mar 9), Citizens Life Sciences (fireside, Mar 10), Jefferies Biotech on the Beach (one-on-ones, Mar 11), and Barclays Global Healthcare (fireside, Mar 11).
Live webcasts of the fireside chats will be available via the company's Investors & Media website, with replay archives retained for 90 days after each event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: AXSM and ABVX up, LEGN, RYTM, NUVL down. Momentum scanner flags ABVX down 6.56%, while CYTK’s move of -0.65% appears stock-specific rather than part of a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings and update | Positive | -10.3% | Q4 and 2025 results with MYQORZO approvals and 2026 expense guidance. |
| Feb 17 | Drug approval | Positive | +0.5% | European Commission approval for MYQORZO tablets for symptomatic oHCM. |
| Feb 12 | Earnings date set | Neutral | +1.9% | Announcement of Q4 2025 results date and related conference call details. |
| Feb 09 | Grant program | Neutral | +1.6% | Grants to HCM-focused patient advocacy groups for education initiatives. |
| Jan 27 | Awareness campaign | Neutral | +1.3% | Launch of "On Track with HCM" awareness program with educational content. |
Recent major fundamental news, including earnings and key approvals, saw mostly modest positive reactions, but the latest earnings update coincided with a sharp negative move.
Over the past weeks, Cytokinetics reported Q4 and full-year 2025 results, highlighted global approvals and early commercial launch of MYQORZO, and issued 2026 expense guidance. Earlier, the European Commission approved MYQORZO across multiple strengths, following prior U.S. and China approvals. The company also communicated its upcoming earnings date, patient advocacy grants, and an HCM awareness campaign. Compared to these fundamental and outreach milestones, today’s conference-participation announcement is a lower-impact, routine investor-relations event.
Market Pulse Summary
This announcement outlines Cytokinetics’ participation in multiple March healthcare and life sciences conferences, offering additional investor access via live and archived webcasts over 90 days. In context, the company recently reported 2025 results, detailed its transition to a commercial-stage biopharma in SEC filings, and secured key MYQORZO approvals. Investors may focus on how management commentary at these events updates expectations around launch progress, R&D spending, and forthcoming HCM trial milestones.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March:
- Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.
- Citizens 2026 Life Sciences Conference: Fireside chat on Tuesday, March 10, 2026 at 9:00 AM Eastern Time in Miami Beach, FL.
- 2026 Jefferies Biotech on the Beach Summit: One-on-one meetings on Wednesday, March 11, 2026 in Miami Beach, FL.
- Barclays 28th Annual Global Healthcare Conference: Fireside chat on Wednesday, March 11, 2026 at 2:30 PM Eastern Time in Miami Beach, FL.
Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When will Cytokinetics (CYTK) present at the Leerink 2026 Global Healthcare Conference?
How can investors watch Cytokinetics (CYTK) fireside chats from the March 2026 conferences?
What is Cytokinetics (CYTK) schedule at the Miami Beach conferences on March 10–11, 2026?
Will the Barclays fireside chat with Cytokinetics (CYTK) be webcast and when is it scheduled?
Are replay archives available for Cytokinetics (CYTK) conference webcasts after the March 2026 events?
Will Cytokinetics (CYTK) hold investor one-on-one meetings during the March 2026 Miami Beach events?
